Bayer: exercises license option for vision loss -January 23, 2024 at 11:03 am EST

BlueRock Therapeutics, a clinical-stage cell therapy company and subsidiary of Bayer, announced that it has exercised its option for an exclusive license to OpCT-001 for the treatment of primary...

Related Keywords

Ahmed Enayetallah ,Head Of Development At Bluerock Therapeutics ,Fujifilm ,Bluerock Therapeutics ,Senior Vice President ,Opsis Therapeutics ,Markets ,